Tags

Type your tag names separated by a space and hit enter

[Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
Vopr Virusol. 2013 Nov-Dec; 58(6):31-5.VV

Abstract

In the current study, we evaluated the neuraminidase-inhibition (NI) antibodies among volunteers during the phase I and phase II of the clinical trials of a monovalent live attenuated influenza vaccine (LAIV) A/17/duck/ Potsdam/86/92(H5N2). The reassortant influenza virus RN2/57-human A(H7N2) containing neuraminidase (NA) from the A/Leningrad/134/17/57(H2N2) was used in NI test. It was shown that two doses of the monovalent LAIV A(H5N2) led to a statistically significant increase in the NI antibodies to vaccine strain NA. More than twofold increase in antibodies was obtained among 19.5-33.3% of vaccinated. The microneutralization test and NI assay results coincidence in the same pairs of sera of the vaccinated volunteers was 73.2%, suggesting thus a statistically significant interdependence between the values of increase in antibodies revealed in both tests (p = 0.04).

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase I
Clinical Trial, Phase II
English Abstract
Journal Article

Language

rus

PubMed ID

24772644

Citation

Smolonogina, T A., et al. "[Evaluation of the Anti-neuraminidase Antibodies in Clinical Trials of the Live Influenza Vaccine of the A(H5N2) Subtype]." Voprosy Virusologii, vol. 58, no. 6, 2013, pp. 31-5.
Smolonogina TA, Desheva IuA, Rekstin AR, et al. [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype]. Vopr Virusol. 2013;58(6):31-5.
Smolonogina, T. A., Desheva, I. u. A., Rekstin, A. R., Mironov, A. N., & Rudenko, L. G. (2013). [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype]. Voprosy Virusologii, 58(6), 31-5.
Smolonogina TA, et al. [Evaluation of the Anti-neuraminidase Antibodies in Clinical Trials of the Live Influenza Vaccine of the A(H5N2) Subtype]. Vopr Virusol. 2013 Nov-Dec;58(6):31-5. PubMed PMID: 24772644.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype]. AU - Smolonogina,T A, AU - Desheva,Iu A, AU - Rekstin,A R, AU - Mironov,A N, AU - Rudenko,L G, PY - 2014/4/30/entrez PY - 2014/4/30/pubmed PY - 2014/5/14/medline SP - 31 EP - 5 JF - Voprosy virusologii JO - Vopr Virusol VL - 58 IS - 6 N2 - In the current study, we evaluated the neuraminidase-inhibition (NI) antibodies among volunteers during the phase I and phase II of the clinical trials of a monovalent live attenuated influenza vaccine (LAIV) A/17/duck/ Potsdam/86/92(H5N2). The reassortant influenza virus RN2/57-human A(H7N2) containing neuraminidase (NA) from the A/Leningrad/134/17/57(H2N2) was used in NI test. It was shown that two doses of the monovalent LAIV A(H5N2) led to a statistically significant increase in the NI antibodies to vaccine strain NA. More than twofold increase in antibodies was obtained among 19.5-33.3% of vaccinated. The microneutralization test and NI assay results coincidence in the same pairs of sera of the vaccinated volunteers was 73.2%, suggesting thus a statistically significant interdependence between the values of increase in antibodies revealed in both tests (p = 0.04). SN - 0507-4088 UR - https://www.unboundmedicine.com/medline/citation/24772644/[Evaluation_of_the_anti_neuraminidase_antibodies_in_clinical_trials_of_the_live_influenza_vaccine_of_the_A_H5N2__subtype]_ L2 - https://medlineplus.gov/flu.html DB - PRIME DP - Unbound Medicine ER -